Interleukin-6 inhibitors acts on the IL-6 receptor and belongs to a group of cytokine receptors that are expressed by leukocytes. IL-6 receptor plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis. However, with the complete knowledge of their role in pathogenesis of different diseases from inflammatory diseases to cancer, makes IL-6 receptors an attractive target among different available treatment modalities. IL-6 trans-signaling blockade with a soluble gp130 protein is currently under pre-clinical studies and have shown promising results in various inflammatory diseases.
INTERLEUKIN-6 (IL-6) INHIBITORS THERAPEUTICS CANDIDATES UNDER DEVELOPMENT (2017)
There are many pharmaceutical companies that are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as combination therapies or single agent therapies. They also allow the development of specific targeted therapies with better drug delivery. For instance, BIOCAD is using BonMab technology platform to develop its drug candidates, BCD 089, for the treatment of autoimmune disorders. Various collaborations between educational institutes and companies, and technological advancements are also contributing to the development of IL-6 inhibitors therapeutics.
As of November 2017, the IL-6 inhibitors therapeutics pipeline comprises of approximately 18 drug candidates in different stages of development.
Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.